Feb 11, 2026 (MarketLine via COMTEX) --
Alvotech increased its share capital by USD 125,000 by issuing 12,500,000 ordinary shares, all subscribed by its subsidiary.
Alvotech (NASDAQ: ALVO) (the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company's subsidiary, Alvotech Manco ehf. (the "subsidiary"), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.
Following the above-mentioned transaction, the subsidiary will hold 16,254,005 shares in the Company, or 4.7% of issued shares, and the number of total issued shares has increased from 334,038,147 to 346,538,147 shares. The number of outstanding shares, consisting of all shares not held as treasury shares by the subsidiary, is unchanged at 330,284,142 shares.
On December 17, 2025, the Company announced that it had provided a stock lending facility to the buyers of Convertible Bonds issued by the Company, for the purpose of facilitating the Convertible Bond investors' hedging activities. The share capital increase is intended to meet the reduction in the number of treasury shares resulting from settlement of the above-mentioned lending of ordinary shares, allowing the Company to continue holding a sufficient number of shares to fulfill the Company's commitments related to various financial obligations, including warrants, convertible financial instruments, and share-based employee compensation.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_474997667/2227/2026-03-10T09:56:35
Copyright (C) 2026 Datamonitor. All rights reserved
